Aegerion Pharmaceuticals Announces Publication in the Lancet of Data From Its Pivotal Phase III Study of Lomitapide in Adult

Aegerion Pharmaceuticals Announces Publication in the Lancet of Data From Its
Pivotal Phase III Study of Lomitapide in Adult Patients with Homozygous
Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, today announced publication in the November
2^nd online version of the Lancet of the 78 week data from the Company's
pivotal Phase III study of lomitapide in adults patients with homozygous
familial hypercholesterolemia (HoFH).

HoFH is a rare, hereditary disease that causes extreme elevation of blood
cholesterol levels.Patients with this disease develop progressive
atherosclerosis at a young age and are at high risk of experiencing premature
cardiovascular events including heart attack or stroke. Despite current
treatments, many patients with HoFH do not survive beyond their mid-30's.

"We are pleased that the Lancet recognizes the importance of this research and
the relevance of the findings in this rare disease with significant medical
needs," said Marc Beer, Chief Executive Officer at Aegerion.

About Lomitapide

Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor that
Aegerion is developing as a once-daily capsule for the treatment of patients
affected with HoFH. MTP exists in both the liver and intestines where it
plays a key role in the formation of lipoproteins containing cholesterol and
triglycerides. Inhibiting MTP has been shown to reduce the level of
cholesterol that the liver and intestines assemble and secrete into the
bloodstream. Currently, there is no MTP inhibitor approved by the FDA for any
indication.

In addition to this pivotal Phase III clinical trial in HoFH completed in
2011, lomitapide has been evaluated in fourteen Phase I and eight Phase II
clinical trials, including one Phase II trial in HoFH patients. An extension
study of the Phase III study is ongoing to assess long-term safety. Over 900
patients have been treated with lomitapide as part of these clinical trials.

The most frequent adverse events in the Phase III clinical trial were
gastrointestinal, and were generally mild to moderate.These events typically
decreased after the patients were established on the maximally tolerated dose.
Elevations in liver enzymes and hepatic fat were also observed in the Phase
III trial.Four patients experienced elevations in liver enzymes of between
five times to eleven times the upper limit of normal. Hepatic fat increased
from a baseline of 1% to 8.3% at week 26, and then stabilized through week
78.

Aegerion submitted an NDA to the Food and Drug Administration (FDA), and a
Marketing Authorization Application (MAA) to the European Medicines Agency
(EMA), requesting approval to market lomitapide as an adjunct to a low-fat
diet and other lipid-lowering therapies, with or without apheresis, to reduce
LDL-C, total cholesterol, apolipoprotein B, and triglycerides in adults with
HoFH.

About Homozygous Familial Hypercholesterolemia (HoFH)

HoFH is a rare genetic lipid disorder that, if left untreated, results in
extremely high cholesterol levels, typically between 400 mg/dL and 1,000
mg/dL. Those affected are at very high risk of experiencing premature
cardiovascular events, such as heart attack or stroke, often experiencing
their first cardiovascular event in their twenties. Despite current
treatments, many patients with HoFH do not survive beyond their mid-30's.

The disease is usually caused by genetic defects that affect the function of
the low-density lipoprotein (LDL) receptor, resulting in impaired or total
loss of function. The LDL receptor is a protein on the surface of cells that
is responsible for binding to and removing cholesterol from the blood. A loss
of LDL receptor function results in elevated accumulation of cholesterol.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on
the development and commercialization of novel, life-altering therapeutics to
treat debilitating and often fatal rare diseases. The company's lead drug
candidate, lomitapide, is in late-stage development for the treatment of
homozygous familial hypercholesterolemia (HoFH), a rare life-threatening
disease characterized by severely elevated cholesterol levels. 

Aegerion is motivated by its commitment to patients first, as well as its core
values of integrity, innovation, responsibility to healthcare providers and
development of employees, with a constant focus on scientific and clinical
excellence. For more information, visit www.aegerion.com.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Michael Lawless, VP, IR
         (857) 242-5028
 
Press spacebar to pause and continue. Press esc to stop.